Asset Details

MbrlCatalogueTitleDetail

Do you wish to reserve the book?

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

by Lim, Elgene , Casalnuovo, Monica Lis , Ruíz Borrego, Manuel , Curigliano, Giuseppe , Kim, Sung-Bae , Cao, Shanshan , Bidard, François-Clément , Harbeck, Nadia , Zhang, Qingyuan , Cramer von Laue, Christoph , O’Shaughnessy, Joyce , Jhaveri, Komal L. , Barrett, Emily , Tokunaga, Eriko , Saura, Cristina , Hung, Chih-Chiang , Carey, Lisa A. , Huang, Chiun-Sheng , Nakamura, Rikiya , Neven, Patrick , Wang, Xuejing Aimee , Aftimos, Philippe , Llombart-Cussac, Antonio , Martinez Rodriguez, Jorge Luis , García Tinoco, María de la Luz , Mattar, André , Sohn, Joohyuk , Smyth, Lillian M. , Pradhan, Kamnesh R.

in Adjuvants / Adult / Aged / Aged, 80 and over / Aminopyridines - administration & dosage / Aminopyridines - adverse effects / Androstadienes / Antineoplastic Combined Chemotherapy Protocols - administration & dosage / Antineoplastic Combined Chemotherapy Protocols - adverse effects / Aromatase / Benzimidazoles - administration & dosage / Benzimidazoles - adverse effects / Benzopyrans - administration & dosage / Benzopyrans - adverse effects / Breast Cancer / Breast Neoplasms - drug therapy / Breast Neoplasms - genetics / Breast Neoplasms - mortality / Breast Neoplasms - pathology / Breast Neoplasms, Male - drug therapy / Breast Neoplasms, Male - mortality / Breast Neoplasms, Male - pathology / Cancer / Cancer therapies / Combination therapy / Cyclin-dependent kinase 4 / Cyclin-dependent kinases / Endocrine therapy / ErbB-2 protein / Estrogen Receptor alpha - analysis / Estrogen Receptor alpha - antagonists & inhibitors / Estrogen Receptor alpha - genetics / Estrogen Receptor alpha - metabolism / Estrogen receptors / Estrogens / Female / Fulvestrant - administration & dosage / Fulvestrant - adverse effects / Hematology / Humans / Kinases / Life Sciences / Male / Metastasis / Middle Aged / Mutation / Oncology / Patients / Progression-Free Survival / Receptor, ErbB-2 - analysis / Survival / Treatment Outcome / Treatments in Oncology / Womens health

2025

Yes Please

Hey, we have placed the reservation for you!

By the way, why not check out events that you can attend while you pick your title.

Oops! Something went wrong.

Looks like we were not able to place the reservation. Kindly try again later.

Are you sure you want to remove the book from the shelf?

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

2025

Confirm

Do you wish to request the book?

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

2025

Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy

How would you like to get it?

Submit

We have requested the book for you!

Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.

Oops! Something went wrong.

Looks like we were not able to place your request. Kindly try again later.

Journal Article

Imlunestrant with or without Abemaciclib in Advanced Breast Cancer

Lim, Elgene,

Casalnuovo, Monica Lis,

Ruíz Borrego, Manuel,

Curigliano, Giuseppe,

Kim, Sung-Bae,

Cao, Shanshan,

Bidard, François-Clément,

Harbeck, Nadia,

Zhang, Qingyuan,

Cramer von Laue, Christoph,

O’Shaughnessy, Joyce,

Jhaveri, Komal L.,

Barrett, Emily,

Tokunaga, Eriko,

Saura, Cristina,

Hung, Chih-Chiang,

Carey, Lisa A.,

Huang, Chiun-Sheng,

Nakamura, Rikiya,

Neven, Patrick,

Wang, Xuejing Aimee,

Aftimos, Philippe,

Llombart-Cussac, Antonio,

Martinez Rodriguez, Jorge Luis,

García Tinoco, María de la Luz,

Mattar, André,

Sohn, Joohyuk,

Smyth, Lillian M.,

Pradhan, Kamnesh R.

2025

Overview

The selective estrogen-receptor degrader imlunestrant plus abemaciclib led to a median progression-free survival of 9.4 months among patients with ER-positive, HER2-negative breast cancer (vs. 5.5 months with imlunestrant alone).

Share this book

Add to My Shelf

Publisher

Massachusetts Medical Society

Subject

Adjuvants

/ Adult

/ Aged

/ Aged, 80 and over

/ Aminopyridines - administration & dosage

/ Aminopyridines - adverse effects

/ Androstadienes